NCI Opens New Immunotherapy Clinical Trial for Mesothelioma
This study offers a reasonable chance of benefit. It would be nice to see if these patients again respond to immunotherapy.”
The FDA approved Opdivo and Yervoy, an immunotherapy combination, for first-line treatment of pleural mesothelioma in 2020. It was the first new systemic approval in more than 16 years. However, it only increased the median overall survival time from 14.1 months to 18.1 months, when compared to standard chemotherapy.
Find Immunotherapy Clinical Trials
Learn how to access mesothelioma clinical trials for immunotherapy.
Sign Up Now
LMB-100 Trial Follows Earlier Study
This latest mesothelioma trial is building on an earlier study at the National Cancer Institute involving pembrolizumab (Keytruda), another immunotherapy drug with a different way of delivering LMB-100.
The earlier trial used systemic delivery. This latest trial involves an intratumor injection of the drug, a novel method that will be watched closely for its potential to better stimulate a more durable immune system response.
LMB-100 works by targeting mesothelin, a tumor-associated antigen that is found highly expressed on the surface of many different types of tumors, including pancreatic, ova...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Chris Elkins Source Type: news
More News: Asbestosis | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Environmental Health | Epithelial Cancer | Food and Drug Administration (FDA) | Immunotherapy | Laboratory Medicine | Learning | Mesothelioma | National Institute for Health and Clinical Excelle | National Institutes of Health (NIH) | Ovarian Cancer | Ovaries | Pancreas | Pancreatic Cancer | Study | Universities & Medical Training | Yervoy